“If you are a U.S. company that does not yet have a China strategy…you need to get moving or risk missing out on a potentially big market,” Brad Loncar, CEO of Loncar Investments, wrote after attending this year’s China Healthcare Investment Conference. Trip reports like these are rolling in, reaffirming what is becoming more and […]

Read more

KYBORA is pleased to announce that it has successfully helped its client STADA Arzneimittel AG license Xlucane – a Ranibizumab (Lucentis) biosimilar to Bausch Health. This latest transaction reinforces KYBORA’s capability in delivering complex cross border transactions working with leading global pharmaceutical companies. “We are seeing an increase in the number of biosimilar deals around […]

Read more

KYBORA is pleased to announce that Anton Leshchenko has joined its team as Managing Director, responsible for expanding KYBORA’s operations in Russia, CIS/CEE, and Africa.  Anton is a senior executive with 18+ years of life science and medical disposables experience with turn around and value addition achievements in territory management and BD&L (both in-/ out-license, […]

Read more

KYBORA is pleased to announce that Rainer Wulf has joined Kybora as a new member of the advisory board. Rainer is a Senior Executive with 30+ years of experience in the pharmaceutical industry, most of them in international positions, starting in sales and followed by Restructuring/Optimization of Sales Organizations, leadership positions in Marketing up to […]

Read more

TYPE & ENTER: